Shanghai MicroPort

Xinmai Medical (688016.SH) develops, produces, sells, and services medical devices for aortic, peripheral vascular, and tumor intervention, aiming to provide life-extending and life-transforming solutions for the medical community.

MicroPort Endovastec’s **Aorfix AAA Endovascular Stent Graft with IntelliFlex Low Profile Delivery System** receives **NMPA Green Channel designation** for innovative medical devices. The system targets minimally invasive aortic aneurysm repair. The designation accelerates regulatory approval for novel medical technologies in China.

Aug 2026MicroPortNews article

MicroPort Endovastec secures NMPA approval for its Fishhawk Mechanical Thrombectomy Device, a tool for removing blood clots in iliac veins via minimally invasive surgery. The device targets acute deep vein thrombosis (DVT) cases, expanding treatment options in China. MicroPort specializes in vascular and orthopedic solutions, leveraging its expertise in interventional therapies.

May 2026MicroPortNews article

MicroPort Endovastec’s SunFlow Drug-Eluting Peripheral Stent System secures NMPA Green Channel designation, accelerating its market access in China. This marks the tenth innovative medical device from the company to receive the designation, reflecting its focus on advancing peripheral vascular interventions. The stent system integrates drug-eluting technology to improve treatment outcomes for peripheral artery disease patients.

May 2026MicroPortNews article

MicroPort Scientific reports that its Endovastec unit drives a notable earnings boost in Q1 2026. The company highlights strong performance from this vascular solutions division, though specific financial figures remain undisclosed.

Apr 2026TipRanksNews article